Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-hospital versus in-hospital ticagrelor initiation in STEMI planned for PCI
2011-000214-19Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ticagrelor in myocardial infarction (MI) and acute coronary syndrome (ACS) (2 arms), sponsored by AstraZeneca. Primary endpoints: TIMI flow grade 3 of culprit vessel at initial angiography and At least 70% ST-segment resolution before PCI. Started Mar 2011; status: completed.
02
Drugs
ticagrelor
03
Conditions
myocardial infarction (MI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2011-000214-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000214-19.